EDITOR'S CORNER Human Vaccines & Immunotherapeutics 12:2, 255; February 2016; © 2016 Taylor & Francis Group, LLC
Letter from the Editor Dear reader, We start this issue of Human Vaccines & Immunotherapeutics by thanking all the Reviewers who peer-reviewed articles submitted to HV&I in 2015. We are pleased to recognize the Top Reviewer of the year, Dr. Xuan-Yi Wang of Fudan University (p 256). We are happy to present a Special Focus on Pneumococcal Vaccines, which features a mixture of research articles, reviews and commentaries Guest-Edited by Prof. Ron Dagan, the head of Pediatric Infectious Disease Unit at Soroka University Medical Center, Israel and an international authority in this field. You can find out more about the Special Focus and its articles in his Editorial (Dagan, p 266). The Immunotherapy section contains a preclinical study of a combination therapy involving a PD-L1 inhibitor and an engineered cellular vaccine for treatment of HER-2-positive breast cancer (Bozeman, p 421), a systematic review of efficacy and safety of Infliximab in patients with psoriasis (Wang, p 431), and a report on the development of a DNA vaccine against Chagas disease (Cerny, p 438). We introduce two research articles on Meningococcal vaccines: a modelling study of potential serogroup replacement in response to MenB vaccination (Hogea, p 451), and a retrospective analysis of disease epidemiology after the introduction of MCC vaccine in Italy (de Waure, p 467). Three Influenza articles deal with therapeutic antibody development for Influenza A (Chan-Hui, p 474), pros and cons of intramuscular and intradermal vaccines in HIV patients (Seo, p 478), and vaccine efficacy in healthcare workers and hospitalized patients (Vanhems, p 485). The Licensed Vaccines section introduces a recommended second booster dose 10 years after primary Yellow Fever vaccination (Campi-Azevedo, p 491), and a trial of the safety and immunogenicity of co-administration of hepatitis A, Hib, meningococcal and DTaP vaccines (Petrecz, p 503). Two articles on Novel Vaccines include an early clinical trial of a tetravalent dengue vaccine in healthy Indian adults (Dubey, p 512), and a preclinical study of an attenuated poxvirus vector-borne vaccine against Crimean-Congo Haemorrhagic Fever (Dowall, p 519). Finally, we present an analysis of HPV vaccine uptake in general practices in France (Thierry, p 528), a retrospective study of Rotavirus-related hospitalizations in Italy (Mattei, p 534), a Public Health report on the low level of vaccine coverage among children of HIV-positive mothers (Tchidjou, p 540), and a preclinical study of Cyclophilin A as an adjuvant for HIV gag DNA vaccine (Hou, p 545). We conclude this issue with a Profile of the International Vaccine Institute (Kim, p 554). Our monthly News, Policy and Profiles (NP&P) track offers a selection of the latest news in the field of vaccines and immunotherapeutics. In this section we also regularly publish opinion pieces on timely, interesting and controversial topics related to vaccines and immunotherapeutics, profiles of companies and organizations, as well as portraits of distinguished scientists in our field. Please contact Acquisitions Editor Adam Weiss ([email protected]) with your ideas for commentaries, opinion pieces, profiles and portraits. Your suggestions for and contributions to our N&P&P track are always welcome! Sincerely, Ronald Ellis, PhD Editor-in-Chief Adam Weiss Acquisitions Editor
http://dx.doi.org/10.1080/21645515.2016.1145528
www.tandfonline.com
Human Vaccines & Immunotherapeutics
255
Letter from the Editor Dear reader, We start this issue of Human Vaccines & Immunotherapeutics by thanking all the Reviewers who peer-reviewed articles submitted to HV&I in 2015. We are pleased to recognize the Top Reviewer of the year, Dr. Xuan-Yi Wang of Fudan University (p 256). We are happy to present a Special Focus on Pneumococcal Vaccines, which features a mixture of research articles, reviews and commentaries Guest-Edited by Prof. Ron Dagan, the head of Pediatric Infectious Disease Unit at Soroka University Medical Center, Israel and an international authority in this field. You can find out more about the Special Focus and its articles in his Editorial (Dagan, p 266). The Immunotherapy section contains a preclinical study of a combination therapy involving a PD-L1 inhibitor and an engineered cellular vaccine for treatment of HER-2-positive breast cancer (Bozeman, p 421), a systematic review of efficacy and safety of Infliximab in patients with psoriasis (Wang, p 431), and a report on the development of a DNA vaccine against Chagas disease (Cerny, p 438). We introduce two research articles on Meningococcal vaccines: a modelling study of potential serogroup replacement in response to MenB vaccination (Hogea, p 451), and a retrospective analysis of disease epidemiology after the introduction of MCC vaccine in Italy (de Waure, p 467). Three Influenza articles deal with therapeutic antibody development for Influenza A (Chan-Hui, p 474), pros and cons of intramuscular and intradermal vaccines in HIV patients (Seo, p 478), and vaccine efficacy in healthcare workers and hospitalized patients (Vanhems, p 485). The Licensed Vaccines section introduces a recommended second booster dose 10 years after primary Yellow Fever vaccination (Campi-Azevedo, p 491), and a trial of the safety and immunogenicity of co-administration of hepatitis A, Hib, meningococcal and DTaP vaccines (Petrecz, p 503). Two articles on Novel Vaccines include an early clinical trial of a tetravalent dengue vaccine in healthy Indian adults (Dubey, p 512), and a preclinical study of an attenuated poxvirus vector-borne vaccine against Crimean-Congo Haemorrhagic Fever (Dowall, p 519). Finally, we present an analysis of HPV vaccine uptake in general practices in France (Thierry, p 528), a retrospective study of Rotavirus-related hospitalizations in Italy (Mattei, p 534), a Public Health report on the low level of vaccine coverage among children of HIV-positive mothers (Tchidjou, p 540), and a preclinical study of Cyclophilin A as an adjuvant for HIV gag DNA vaccine (Hou, p 545). We conclude this issue with a Profile of the International Vaccine Institute (Kim, p 554). Our monthly News, Policy and Profiles (NP&P) track offers a selection of the latest news in the field of vaccines and immunotherapeutics. In this section we also regularly publish opinion pieces on timely, interesting and controversial topics related to vaccines and immunotherapeutics, profiles of companies and organizations, as well as portraits of distinguished scientists in our field. Please contact Acquisitions Editor Adam Weiss ([email protected]) with your ideas for commentaries, opinion pieces, profiles and portraits. Your suggestions for and contributions to our N&P&P track are always welcome! Sincerely, Ronald Ellis, PhD Editor-in-Chief Adam Weiss Acquisitions Editor
http://dx.doi.org/10.1080/21645515.2016.1145528
www.tandfonline.com
Human Vaccines & Immunotherapeutics
255
